NO20030139L - Farmasöytiske preparater inneholdende DDS forbindelser - Google Patents

Farmasöytiske preparater inneholdende DDS forbindelser

Info

Publication number
NO20030139L
NO20030139L NO20030139A NO20030139A NO20030139L NO 20030139 L NO20030139 L NO 20030139L NO 20030139 A NO20030139 A NO 20030139A NO 20030139 A NO20030139 A NO 20030139A NO 20030139 L NO20030139 L NO 20030139L
Authority
NO
Norway
Prior art keywords
pharmaceutical preparations
preparations containing
dds compounds
containing dds
compounds
Prior art date
Application number
NO20030139A
Other languages
English (en)
Other versions
NO20030139D0 (no
Inventor
Masayuki Takahashi
Shuichi Sugie
Masahito Takeuchi
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of NO20030139D0 publication Critical patent/NO20030139D0/no
Publication of NO20030139L publication Critical patent/NO20030139L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20030139A 2000-07-13 2003-01-10 Farmasöytiske preparater inneholdende DDS forbindelser NO20030139L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000213083 2000-07-13
PCT/JP2001/006020 WO2002005855A1 (fr) 2000-07-13 2001-07-11 Compositions pharmaceutiques contenant des composes dds

Publications (2)

Publication Number Publication Date
NO20030139D0 NO20030139D0 (no) 2003-01-10
NO20030139L true NO20030139L (no) 2003-03-13

Family

ID=18708899

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030139A NO20030139L (no) 2000-07-13 2003-01-10 Farmasöytiske preparater inneholdende DDS forbindelser

Country Status (12)

Country Link
US (1) US6815435B2 (no)
EP (1) EP1308171A1 (no)
KR (1) KR20030023697A (no)
CN (1) CN1556712A (no)
AR (1) AR031714A1 (no)
AU (1) AU2001271037A1 (no)
BR (1) BR0112417A (no)
CA (1) CA2415922A1 (no)
MX (1) MXPA03000387A (no)
NO (1) NO20030139L (no)
RU (1) RU2003100532A (no)
WO (1) WO2002005855A1 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000734A1 (fr) * 2000-06-29 2002-01-03 Daiichi Pharmaceutical Co., Ltd. Compose dds et son procede de preparation
TWI320713B (no) * 2001-06-01 2010-02-21 Neochemir Inc
TW200306314A (en) * 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
KR20050085218A (ko) * 2002-12-10 2005-08-29 마사야 다나카 피부 외용재 및 그것을 사용한 외용 지양제, 주름 제거도구
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
AU2013263795B2 (en) * 2010-03-29 2015-09-17 Ferring B.V. A fast dissolving pharmaceutical composition
NZ619857A (en) 2010-03-29 2015-05-29 Ferring Bv A fast dissolving pharmaceutical composition
US9731018B2 (en) 2011-09-16 2017-08-15 Ferring B.V. Fast dissolving pharmaceutical composition
SI2907824T1 (en) 2012-10-11 2018-06-29 Daiichi Sankyo Company, Limited THE HEALTHY KJUBIER OF THE PROTITEL
US9872924B2 (en) 2012-10-19 2018-01-23 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
WO2015098099A1 (ja) 2013-12-25 2015-07-02 第一三共株式会社 抗trop2抗体-薬物コンジュゲート
EP3466976B1 (en) 2014-01-31 2021-09-08 Daiichi Sankyo Company, Limited Anti-her2 antibody-drug conjugate
ES2754348T3 (es) 2014-04-10 2020-04-17 Daiichi Sankyo Co Ltd Conjugado de (anticuerpo anti-HER2)-fármaco
SI3129063T1 (sl) 2014-04-10 2021-08-31 Daiichi Sankyo Company PROTI-HER3 konjugat zdravila s protitelescem
US9855339B2 (en) 2014-12-26 2018-01-02 Nippon Kayaku Kabushiki Kaisha Pharmaceutical preparation of camptothecin-containing polymer derivative
BR112017027690A2 (pt) 2015-06-29 2018-10-09 Daiichi Sankyo Co Ltd “método para produção de uma composição de conjugado anticorpo-fármaco, e, composição de conjugado anticorpo-fármaco
RU2726415C2 (ru) 2015-09-03 2020-07-14 Ниппон Каяку Кабусики Каися Фармацевтическая композиция, содержащая полимерное производное камптотецина
EP3424513A4 (en) 2016-03-01 2019-10-23 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL PREPARATION WITH CAMPTOTHECINOUS POLYMER DERIVATIVE
US11273155B2 (en) 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
US11434289B2 (en) 2017-01-17 2022-09-06 Daiichi Sankyo Company, Limited Anti-GPR20 antibody and anti-GPR20 antibody-drug conjugate
TWI794230B (zh) 2017-05-15 2023-03-01 日商第一三共股份有限公司 抗cdh6抗體及抗cdh6抗體-藥物結合物、以及其製造方法
KR102422860B1 (ko) 2017-08-31 2022-07-19 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 신규 제조 방법
BR112020003646A2 (pt) 2017-08-31 2020-09-01 Daiichi Sankyo Company, Limited cristais, métodos para produção de cristais e de um conjugado anticorpo-fármaco, e, sal.
CA3100745A1 (en) 2018-05-18 2019-11-21 Glycotope Gmbh Anti-muc1 antibody
MX2022000450A (es) 2019-07-10 2022-04-25 Cybrexa 3 Inc Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos.
BR112022000337A2 (pt) 2019-07-10 2022-04-12 Cybrexa 2 Inc Conjugados de peptídeos de citotoxinas como terapêuticos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5711909A (en) * 1980-06-23 1982-01-21 Shionogi & Co Ltd Stable freeze-dried preparation of beta-lactam
JPS61165322A (ja) * 1985-01-14 1986-07-26 Microbial Chem Res Found スパガリン類の注射用凍結乾燥製剤
KR19990044445A (ko) 1995-09-13 1999-06-25 니뽄 신야쿠 가부시키가이샤 Pge1 함유 동결건조 제제 및 그 제법
HUP9900812A3 (en) 1996-02-19 1999-11-29 Nycomed Imaging As Thermally stabilized contrast agent
WO1997035135A1 (en) * 1996-03-19 1997-09-25 The Morgan Crucible Company Plc. A conduit
JPH10212241A (ja) 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Bdnfを安定に含有する製剤
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
WO2000018401A1 (fr) 1998-09-29 2000-04-06 Takeda Chemical Industries, Ltd. Composition de medicament antimycotique

Also Published As

Publication number Publication date
US6815435B2 (en) 2004-11-09
BR0112417A (pt) 2003-07-01
CA2415922A1 (en) 2002-01-24
AU2001271037A1 (en) 2002-01-30
WO2002005855A1 (fr) 2002-01-24
EP1308171A1 (en) 2003-05-07
KR20030023697A (ko) 2003-03-19
RU2003100532A (ru) 2004-07-20
AR031714A1 (es) 2003-10-01
NO20030139D0 (no) 2003-01-10
US20030148931A1 (en) 2003-08-07
MXPA03000387A (es) 2003-09-22
CN1556712A (zh) 2004-12-22

Similar Documents

Publication Publication Date Title
NO20030139L (no) Farmasöytiske preparater inneholdende DDS forbindelser
NO20071303L (no) Farmasoytiske preparater
NO20033556D0 (no) Farmasöytiske preparater
IS5953A (is) Lyfjablöndur úr örgerðum eplerenonum
NO20021401D0 (no) Konazolinforbindelser og farmasöytiske preparater inneholdende slike forbindelser
ITTO20010008A0 (it) Formulazione farmaceutica
NO20020304L (no) Konserverte farmasoytiske preparater
NO20020464L (no) Flerkomponents farmasöytisk doseringsform
NO20022970D0 (no) Hydrogel-drevet medikamentdoseringsform
NO992339D0 (no) Farmas°ytiske formuleringer
ATE238812T1 (de) Voriconazol-enthaltende pharmazeutische zubereitungen
NO20030627D0 (no) Hydrogel-drevet medikament doseringsform
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
MXPA03001425A (es) Compuestos farmaceuticos.
ATE332132T1 (de) Verbesserte arzneizubereitungen enthaltend ritonavir
NO20026013L (no) Medisinske preparater inneholdende propenonderivater
NO20014926D0 (no) Farmasöytiske forbindelser
ATE324883T1 (de) Pharmazeutische zusammensetzung enthaltend lumiracoxib
EE200300135A (et) Trüptamiini derivaadid ja analoogsed ühendid ningneid sisaldavad farmatseutilised preparaadid
DE69926012D1 (de) Arzneizubereitungen
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
NO20016430L (no) Farmasöytisk kompleks
AR025867A1 (es) Formulacion portasdora farmaceutica
DE69906934D1 (de) Arzneizubereitungen
FI20012242A0 (fi) Uudet farmaseuttiset yhdisteet

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application